IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.
Reasonable growth potential with questionable track record.
Share Price & News
How has IQVIA Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IQV's share price has been volatile over the past 3 months.
7 Day Return
US Life Sciences
1 Year Return
US Life Sciences
Return vs Industry: IQV underperformed the US Life Sciences industry which returned -5.7% over the past year.
Return vs Market: IQV underperformed the US Market which returned -10.7% over the past year.
Price Volatility Vs. Market
How volatile is IQVIA Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StIs IQVIA Holdings (NYSE:IQV) Using Too Much Debt?
1 month ago | Simply Wall StShould You Be Worried About Insider Transactions At IQVIA Holdings Inc. (NYSE:IQV)?
2 months ago | Simply Wall StAt US$155, Is It Time To Put IQVIA Holdings Inc. (NYSE:IQV) On Your Watch List?
Is IQVIA Holdings undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: IQV ($107.86) is trading above our estimate of fair value ($95.03)
Significantly Below Fair Value: IQV is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: IQV is poor value based on its PE Ratio (110.2x) compared to the Life Sciences industry average (30x).
PE vs Market: IQV is poor value based on its PE Ratio (110.2x) compared to the US market (13.1x).
Price to Earnings Growth Ratio
PEG Ratio: IQV is poor value based on its PEG Ratio (3.4x)
Price to Book Ratio
PB vs Industry: IQV is good value based on its PB Ratio (3.5x) compared to the US Life Sciences industry average (4.4x).
How is IQVIA Holdings forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IQV's forecast earnings growth (32.4% per year) is above the savings rate (1.7%).
Earnings vs Market: IQV's earnings (32.4% per year) are forecast to grow faster than the US market (12.3% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: IQV's revenue (6.1% per year) is forecast to grow slower than the US market (7.2% per year).
High Growth Revenue: IQV's revenue (6.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IQV's Return on Equity is forecast to be high in 3 years time (26.3%)
How has IQVIA Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IQV has high quality earnings.
Growing Profit Margin: IQV's current net profit margins (1.7%) are lower than last year (2.5%).
Past Earnings Growth Analysis
Earnings Trend: IQV's earnings have grown by 8.2% per year over the past 5 years.
Accelerating Growth: IQV's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: IQV had negative earnings growth (-26.3%) over the past year, making it difficult to compare to the Life Sciences industry average (21.5%).
Return on Equity
High ROE: IQV's Return on Equity (3.6%) is considered low.
How is IQVIA Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: IQV's short term assets ($4.1B) exceed its short term liabilities ($3.9B).
Long Term Liabilities: IQV's short term assets ($4.1B) do not cover its long term liabilities ($13.0B).
Debt to Equity History and Analysis
Debt Level: IQV's debt to equity ratio (186.4%) is considered high.
Reducing Debt: IQV had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: IQV's debt is not well covered by operating cash flow (12.1%).
Interest Coverage: IQV's interest payments on its debt are not well covered by EBIT (2x coverage).
Inventory Level: IQV has a low level of unsold assets or inventory.
Debt Coverage by Assets: IQV's debt is not covered by short term assets (assets are 0.4x debt).
What is IQVIA Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IQV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate IQV's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IQV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IQV's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: IQV is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IQV's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ari Bousbib (58yo)
Mr. Ari Bousbib serves as Chairman and Chief Executive Officer at IQVIA Holdings Inc. since October 2016 and also serves as its President. He has been the Chairman, Chief Executive Officer and President of ...
CEO Compensation Analysis
Compensation vs Market: Ari's total compensation ($USD22.14M) is above average for companies of similar size in the US market ($USD11.77M).
Compensation vs Earnings: Ari's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
|Executive VP & CFO||4.33yrs||US$2.95m||0.0084% $1.7m|
|Executive VP||2.08yrs||US$2.37m||no data|
|President of Research & Development Solutions||3.42yrs||US$2.64m||0.0065% $1.3m|
|President of Technology & Commercial Solutions||3.5yrs||US$2.61m||no data|
|Senior VP||1.42yrs||no data||no data|
|Senior VP||no data||no data||no data|
|Chief Information Officer||5.33yrs||no data||no data|
|Vice President of Investor Relations||no data||no data||no data|
|Senior Vice President of Strategy||no data||no data||no data|
Experienced Management: IQV's management team is considered experienced (3.5 years average tenure).
|Independent Director||3.5yrs||US$282.39k||0.038% $7.6m|
|Independent Director||12.25yrs||no data||no data|
|Lead Director||1.75yrs||US$357.39k||0.0043% $864.7k|
|Independent Director||9.92yrs||US$309.89k||0.0062% $1.2m|
|Independent Director||17.25yrs||no data||no data|
|Independent Director||3.5yrs||US$334.89k||0.032% $6.4m|
|Independent Director||2.75yrs||US$314.89k||0.0030% $604.1k|
|Independent Director||3.5yrs||no data||no data|
|Independent Director||3.5yrs||no data||no data|
Experienced Board: IQV's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: IQV insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
IQVIA Holdings Inc.'s company bio, employee growth, exchange listings and data sources
- Name: IQVIA Holdings Inc.
- Ticker: IQV
- Exchange: NYSE
- Founded: 1982
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$20.203b
- Shares outstanding: 192.82m
- Website: https://www.iqvia.com
Number of Employees
- IQVIA Holdings Inc.
- 4820 Emperor Boulevard
- North Carolina
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IQV||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||May 2013|
|QTS||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||May 2013|
|0JDM||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||May 2013|
|IQV *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||May 2013|
|IQVH||WBAG (Wiener Boerse AG)||Yes||Common Stock||AT||EUR||May 2013|
|I1QV34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH 4 REPR 1 COM||BR||BRL||Jan 2020|
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support services; and strategic planning and design services, as well as clinical trial, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/03 02:01|
|End of Day Share Price||2020/04/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.